Role of Asymmetrical Dimethylarginine in Diabetic Microvascular Complications. Issue 4 (October 2016)

• Record Type: Journal Article
• Authors: Du, Mei-Rong; Ju, Gui-Xia; Li, Nian-Sheng; Jiang, Jun-Lin
• Is Part Of: Journal of cardiovascular pharmacology. Volume 68:Issue 4(2016)
• Publication Date: 2016-10
• Subjects: ADMA -- microvascular complications -- diabetes; Cardiovascular Diseases -- drug therapy -- Periodicals; Cardiovascular System -- drug effects -- Periodicals; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular agents; Cardiovascular pharmacology; Periodicals; 615.7105
• DOI: 10.1097/FJC.0000000000000414
• Languages: English
• ISSNs: 0160-2446

Abstract

Abstract : Abstract: Microvascular complications are the leading causes of acquired blindness, end-stage renal failure, and varieties of neuropathy associated with diabetes. Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is involved in endothelial dysfunction, oxidative stress, and inflammation associated with the progression of diabetic microvascular complications. Elevated ADMA has been detected in experimental animals and patients with diabetic microangiopathy like retinopathy, nephropathy, and neuropathy. In the review, we focus on the role of ADMA in the pathobiology of major microvascular complications of diabetes.